Were Analysts Bearish BioDelivery Sciences International, Inc. (NASDAQ:BDSI) This Week?

October 12, 2017 - By Louis Casey

 Were Analysts Bearish BioDelivery Sciences International, Inc. (NASDAQ:BDSI) This Week?
Investors sentiment increased to 1 in 2017 Q2. Its up 0.04, from 0.96 in 2017Q1. It is positive, as 6 investors sold BioDelivery Sciences International, Inc. shares while 16 reduced holdings. 8 funds opened positions while 14 raised stakes. 19.04 million shares or 0.51% more from 18.95 million shares in 2017Q1 were reported.
Buckingham Asset Llc accumulated 0.02% or 35,600 shares. Vanguard Gru reported 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Sterling Investment Mngmt holds 0.18% or 50,000 shares in its portfolio. Citigroup Inc holds 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 1,000 shares. Art Ltd Liability Company holds 0% or 26,755 shares. Wells Fargo And Mn invested in 14,907 shares or 0% of the stock. Walleye Trading has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 32,000 shares. Price T Rowe Assocs Md stated it has 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Eam Invsts Llc owns 481,472 shares. Blackrock, a New York-based fund reported 1.16 million shares. Broadfin Limited Liability invested in 5.12 million shares. Moreover, One Trading L P has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Jacobs Levy Equity Management Inc, a New Jersey-based fund reported 200,049 shares. Bancorporation Of New York Mellon Corp owns 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 44,280 shares. 121,871 were accumulated by Morgan Stanley.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 6 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery Sciences International had 23 analyst reports since August 16, 2015 according to SRatingsIntel. Roth Capital maintained it with “Buy” rating and $9 target in Friday, March 11 report. The rating was initiated by Piper Jaffray with “Overweight” on Monday, February 8. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) earned “Buy” rating by FBR Capital on Wednesday, June 21. The company was maintained on Friday, June 23 by H.C. Wainwright. The company was maintained on Wednesday, August 9 by Piper Jaffray. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Monday, July 24 by H.C. Wainwright. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Friday, September 15 by Piper Jaffray. FBR Capital maintained the stock with “Mkt Perform” rating in Tuesday, November 10 report. Janney Capital initiated BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Tuesday, October 27 with “Neutral” rating. The firm earned “Buy” rating on Wednesday, November 4 by Cantor Fitzgerald. Below is a list of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) latest ratings and price target changes.

15/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
08/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Initiate
23/08/2017 Broker: Cantor Fitzgerald Rating: Buy Maintain
14/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $4.0000 Maintain
09/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0000 Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0000 Maintain
24/07/2017 Broker: Janney Capital Rating: Buy New Target: $4.0000
24/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
10/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0000 Maintain
23/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain

About 835,257 shares traded or 50.67% up from the average. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 24.37% since October 12, 2016 and is uptrending. It has outperformed by 7.67% the S&P500.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The company has market cap of $170.59 million. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. It has a 268.56 P/E ratio. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Seekingalpha.com which released: “BioDelivery Sciences: Belbuca Transition Appears To Have Worked” on May 07, 2017, also Seekingalpha.com with their article: “BioDelivery Sciences: Change Is Good?” published on September 29, 2017, Prnewswire.com published: “BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides …” on May 15, 2017. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Prnewswire.com and their article: “BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of …” published on May 02, 2017 as well as Prnewswire.com‘s news article titled: “BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in …” with publication date: March 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com